Jeffrey S. Glenn, M.D., Ph.D.
Academic Appointments
- Associate Professor, Medicine - Gastroenterology & Hepatology
- Member, Bio-X
- Member, Cancer Center
Contact Information
-
Clinical Offices
Gastroenterology 269 Campus Dr. - CCSR Bldg Rm. 3115 MC: 5187 Stanford, CA 94305 Tel Work (650) 725-3373 Fax (650) 723-3032
-
Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Gastroenterology
Administrative Appointments
- Director, Center for Hepatitis and Liver Tissue Engineering (2006 - present)
Honors and Awards
- Summa cum laude, U.C. Berkeley (1984)
- Physician Postdoctoral Fellowship Award, Howard Hughes Medical Institute (1995-1998)
- Career Award, Burroughs Wellcome Fund (1998-2005)
- Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund (2005-2010)
- Elected member, American Society for Clinical Investigation (2008)
Professional Education
| Fellowship: | SUMC - Graduate Medical Education, CA (1999) |
| Residency: | SUMC - Graduate Medical Education, CA (1995) |
| Internship: | SUMC - Graduate Medical Education, CA (1994) |
| Medical Education: | UCSF School of Medicine, CA (1993) |
| Ph.D.: | U.C.S.F., Biochemistry and Biophysics (1992) |
Postdoctoral Advisees
Nam-Joon Cho, Hadas Dvory-Sobol, Choongho Lee, James Lue, Phillip Pang
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | Eiger BioPharmaceuticals, Epiphany, Presidio Pharmaceuticals, Romark Laboratories |
| Equity: | Eiger BioPharmaceuticals, Epiphany, Presidio Pharmaceuticals, Romark Laboratories |
| Service on Board of Directors: | Eiger BioPharmaceuticals |
Scientific Focus
Research Interests
Dr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Current projects aim to better understand the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses-both as a mechanism of intracellular trafficking and trigger of virus assembly, and as a target for a promising antiviral treatment. The function and cell biology of the hepatitis C virus (HCV) non-structural proteins are also being studied. Here the focus is on identifying key determinants of pathogenesis and designing novel antiviral strategies. Other interests include exploitation of hepatic stem cells, development of a small animal model for HCV, and engineered human liver tissues.
Publications
- Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel. Biomed Mater. 2009; (1): 11001
- The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology. 2009; (5): 1827-35
- Alpha-helical peptide-induced vesicle rupture revealing new insight into the vesicle fusion process as monitored in situ by quartz crystal microbalance-dissipation and reflectometry. Anal Chem. 2009; (12): 4752-61
- The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One. 2009; (8): e6579
- The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl. 2009; (9): 1126-32
Help